ROCKVILLE, Md., Apr. 15, 2021 /PRNewswire/ — American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of AGT103-T, a single dose, autologous cell therapy intended to cure the disease.
This investment places Gaingels alongside private investors who believe deeply in AGT’s mission, rapid drug development platform, and gene and cell therapy programs for HIV, cancer, and PKU.
Image: https://www.americangene.com
{iframe}https://www.americangene.com/press-releases/lgbt-investment-firm-gaingels-joins-american-gene-technologies-mission-to-cure-hiv-and-other-serious-human-diseases/{/iframe}